Akso Health Group (AHG) recently reported a substantial jump in quarterly revenue alongside improved net profit. However, weak operating efficiency, financial health concerns, and limited disclosures are keeping investors focused on the durability of this shift.

Despite the recent revenue headline, Akso Health Group’s share price has come under pressure, with a 30 day share price return down 17.79% and a 90 day share price return down 43.22%, even as the three year total shareholder return is very large. This pattern suggests earlier enthusiasm has cooled and investors are reassessing the company’s risks and disclosure gaps relative to its current US$1.34 share price.

If Akso Health Group’s swings have you thinking about where else growth stories might emerge in healthcare, this could be a good moment to scan 41 healthcare AI stocks.

So with Akso Health Group’s share price sliding even as recent revenue and net profit figures improve, is the stock trading below what the fundamentals might justify, or is the market already factoring in any future growth story?

Preferred Price to Book of 5.8x: Is It Justified for Akso Health Group Stock?

On the latest figures, Akso Health Group trades at a P/B ratio of 5.8x, while the broader US Healthcare sector sits at 2.5x. This leaves the stock looking expensive relative to the typical company in its industry at the current $1.34 share price.

The P/B ratio compares a company’s market value to its book value. In other words, it shows what investors are paying for each dollar of net assets on the balance sheet. For Akso Health Group, a P/B of 5.8x means the market is pricing its equity at almost six times its recorded net assets, even though the company is currently loss making and has seen losses increase at an annual rate of 36.7% over the past five years.

Compared with the US Healthcare industry average P/B of 2.5x, Akso Health Group’s 5.8x multiple is more than double. This suggests investors are paying a higher price for each dollar of book value than they typically would for the sector. At the same time, the stock is described as good value against a much higher peer group average P/B of 988.1x, which points to a very wide spread of valuations across its closer peers rather than clear evidence of a bargain at the current level.

Result: Price-to-book of 5.8x (OVERVALUED) compared to the broader US Healthcare industry.

However, Akso Health Group’s current loss of US$135.67 million, along with the concentration of all revenue in China, leaves little margin for error if conditions become tougher.

Next Steps

If this mix of higher valuation and balance sheet questions around Akso Health Group leaves you cautious, act now by reviewing the company’s 3 important warning signs.

Looking for more investment ideas beyond Akso Health Group?

Do not stop with Akso Health Group. Broaden your watchlist now with focused stock ideas built from clear financial filters in the Simply Wall Street Screener.

• Target steadier journeys by checking out 65 resilient stocks with low risk scores that may help reduce sharp portfolio swings.
• Hunt for potential value candidates by reviewing the screener containing 20 high quality undiscovered gems before they gain wider attention.
• Strengthen your income focus by scanning 8 dividend fortresses that could suit investors prioritizing regular cash returns.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.